| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,872 |
8,328 |
$372K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,979 |
2,984 |
$129K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
2,075 |
1,494 |
$99K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,383 |
2,376 |
$67K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,370 |
1,110 |
$56K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
102 |
96 |
$11K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
33 |
26 |
$3K |
| 96127 |
|
840 |
652 |
$2K |
| 80305 |
|
475 |
297 |
$2K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
586 |
430 |
$1K |
| 72100 |
|
128 |
98 |
$998.08 |
| 64493 |
|
18 |
15 |
$620.96 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
203 |
188 |
$614.34 |
| 64494 |
|
18 |
15 |
$301.78 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14 |
13 |
$210.85 |
| 99406 |
|
52 |
37 |
$181.01 |
| 1123F |
|
360 |
321 |
$0.01 |
| 1100F |
|
367 |
325 |
$0.00 |
| 0518F |
|
32 |
29 |
$0.00 |
| G9900 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified |
13 |
12 |
$0.00 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
177 |
160 |
$0.00 |
| G8400 |
Patient with central dual-energy x-ray absorptiometry (dxa) results not documented, reason not given |
16 |
15 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
14 |
14 |
$0.00 |
| G8432 |
Depression screening not documented, reason not given |
192 |
166 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
116 |
99 |
$0.00 |
| 3017F |
|
204 |
182 |
$0.00 |
| 1036F |
|
63 |
53 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
16 |
14 |
$0.00 |
| G9716 |
Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason |
99 |
89 |
$0.00 |